Download PDF
Dtsch Med Wochenschr 2006; 131(18): 1031-1034
DOI: 10.1055/s-2006-939891
Arzneimittel & Pharmakotherapie | Review article
Pneumologie
© Georg Thieme Verlag Stuttgart · New York

Bosentan - Neues Standbein der Therapie der pulmonalen Hypertonie?

Bosentan: a new pillar in the treatment of pulmonary hypertension?J. Matthes1 , F. Groner2
  • 1Institut für Pharmakologie, Universität zu Köln
  • 2Institut für Pathophysiologie, Universität Essen
Further Information

Publication History

eingereicht: 14.9.2005

akzeptiert: 12.1.2006

Publication Date:
03 May 2006 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Bosentan - pulmonal-arterielle Hypertonie

Key words

Bosentan - pulmonary hypertension

Literatur

  • 1 McLaughlin V V, Rich S. Pulmonary hypertension.  Curr Probl Cardiol. 2004;  29 575-634
    Google Scholar
  • 2 Galie N, Manes A, Uguccioni L. et al . Primary pulmonary hypertension: insights into pathogenesis from epidemiology.  Chest. 1998;  114 184S-194S (3 Suppl)
    Google Scholar
  • 3 D’Alonzo G E, Barst R J, Ayres S M. et al . Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.  Ann Intern Med. 1991;  115 343-349
    Google Scholar
  • 4 McLaughlin V V, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.  Circulation. 2002;  106 1477-1482
    Google Scholar
  • 5 Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension.  N Engl J Med. 2004;  351 1425-1436
    Google Scholar
  • 6 Badesch D B, Abman S H, Ahearn G S. et al . Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.  Chest. 2004;  126 35S-62S (Suppl 1)
    Google Scholar
  • 7 Russell F D, Davenport A P. Secretory pathways in endothelin synthesis.  Br J Pharmacol. 1999;  126 391-398
    Google Scholar
  • 8 Dupuis J, Stewart D J, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1.  Circulation. 1996;  94 1578-1584
    Google Scholar
  • 9 McCulloch K M, MacLean M R. Endothelin B receptor-mediated contraction of human and rat pulmonary resistance arteries and the effect of pulmonary hypertension on endothelin responses in the rat.  J Cardiovasc Pharmacol. 1995;  26 S169-176 (Suppl 3)
    Google Scholar
  • 10 Jasmin J F, Lucas M, Cernacek P, Dupuis J. Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension.  Circulation. 2001;  103 314-318
    Google Scholar
  • 11 Hirata Y, Emori T, Eguchi S. et al . Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells.  J Clin Invest. 1993;  91 1367-1373
    Google Scholar
  • 12 Filep J G, Herman F, Battistini B, Chabrier P E, Braquet P, Sirois P. Antiaggregatory and hypotensive effects of endothelin-1 in beagle dogs: role for prostacyclin.  J Cardiovasc Pharmacol. 1991;  17 S216-218 (Suppl 7)
    Google Scholar
  • 13 Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.  N Engl J Med. 1995;  333 214-221
    Google Scholar
  • 14 Tuder R M, Cool C D, Geraci M W. et al . Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension.  Am J Respir Crit Care Med. 1999;  159 1925-1932
    Google Scholar
  • 15 Giaid A, Yanagisawa M, Langleben D. et al . Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.  N Engl J Med. 1993;  328 1732-1739
    Google Scholar
  • 16 Dupuis J, Cernacek P, Tardif J C. et al . Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension.  Am Heart J. 1998;  135 614-620
    Google Scholar
  • 17 Rubens C, Ewert R, Halank M. et al . Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension.  Chest. 2001;  120 1562-1569
    Google Scholar
  • 18 Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension.  Cardiovasc Res. 2004;  61 227-237
    Google Scholar
  • 19 Bauer M, Wilkens H, Langer F, Schneider S O, Lausberg H, Schafers H J. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension.  Circulation. 2002;  105 1034-1036
    Google Scholar
  • 20 Clozel M, Breu V, Gray G A. et al . Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.  J Pharmacol Exp Ther. 1994;  270 228-235
    Google Scholar
  • 21 Teerlink J R, Carteaux J P, Sprecher U, Loffler B M, Clozel M, Clozel J P. Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs.  Am J Physiol. 1995;  268 H432-440
    Google Scholar
  • 22 Weber C, Schmitt R, Birnboeck H. et al . Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.  Clin Pharmacol Ther. 1996;  60 124-137
    Google Scholar
  • 23 Clozel M. Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit?.  Ann Med. 2003;  35 605-613
    Google Scholar
  • 24 Chen S J, Chen Y F, Meng Q C, Durand J, Dicarlo V S, Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats.  J Appl Physiol. 1995;  79 2122-2131
    Google Scholar
  • 25 Kim H, Yung G L, Marsh J J. et al . Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension.  Eur Respir J. 2000;  15 640-648
    Google Scholar
  • 26 Dingemanse J, van Giersbergen P L. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.  Clin Pharmacokinet. 2004;  43 1089-1115
    Google Scholar
  • 27 Weber C, Gasser R, Hopfgartner G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects.  Drug Metab Dispos. 1999;  27 810-815
    Google Scholar
  • 28 van Giersbergen P L, Halabi A, Dingemanse J. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.  Br J Clin Pharmacol. 2002;  53 589-595
    Google Scholar
  • 29 Cohen H, Chahine C, Hui A, Mukherji R. Bosentan therapy for pulmonary arterial hypertension.  Am J Health Syst Pharm. 2004;  61 1107-1119
    Google Scholar
  • 30 Fachinformation zu Tracleer®,. Actelion Ltd. (London) 2004
    Google Scholar
  • 31 Packer M, McMurray J, Massie B M. et al . Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study.  J Card Fail. 2005;  11 12-20
    Google Scholar
  • 32 Rubin L J, Badesch D B, Barst R J. et al . Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 2002;  346 896-903
    Google Scholar
  • 33 Fattinger K, Funk C, Pantze M. et al . The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions.  Clin Pharmacol Ther. 2001;  69 223-231
    Google Scholar
  • 34 Weiss B M, Zemp L, Seifert B, Hess O M. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996.  J Am Coll Cardiol. 1998;  31 1650-1657
    Google Scholar
  • 35 Channick R, Simonneau G, Sitbon O. et al . Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study.  Lancet. 2001;  358 1119-1123
    Google Scholar
  • 36 Liu C, Cheng J. Endothelin receptor antagonists for pulmonary arterial hypertension.  Cochrane Database Syst Rev. 2005;  1 CD004434
    Google Scholar
  • 37 Miyamoto S, Nagaya N, Satoh T. et al . Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.  Am J Respir Crit Care Med. 2000;  161 487-492
    Google Scholar
  • 38 McLaughlin V V, Sitbon O, Badesch D B. et al . Survival with first-line bosentan in patients with primary pulmonary hypertension.  Eur Respir J. 2005;  25 244-249
    Google Scholar
  • 39 Galie N, Hinderliter A L, Torbicki A. et al . Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.  J Am Coll Cardiol. 2003;  41 1380-1386
    Google Scholar
  • 40 Hoeper M M, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.  Eur Respir J. 2003;  22 330-334
    Google Scholar
  • 41 Humbert M, Barst R J, Robbins I M. et al . Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.  Eur Respir J. 2004;  24 353-359
    Google Scholar
  • 42 Ivy D D, Doran A, Claussen L, Bingaman D, Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan.  Am J Cardiol. 2004;  93 943-946
    Google Scholar
  • 43 Wilkins M R, Paul G A, Strange J W. et al . Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.  Am J Respir Crit Care Med. 2005;  171 1292-1297
    Google Scholar
  • 44 Hoeper M M, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.  Eur Respir J. 2004;  24 1007-1010
    Google Scholar
  • 45 Olschewski H, Ghofrani A, Enke B. et al . Therapy of pulmonary arterial hypertension.  Internist (Berl). 2005;  46 341-349
    Google Scholar
  • 46 Matthes J, Mathen F, Herzig S, Wassermann K. Therapie der schweren pulmonalen Hypertonie mit Prostazyklin und Iloprost.  Dtsch Med Wochenschr. 2001;  126 631-637
    Google Scholar

Dr. Jan Matthes

Institut für Pharmakologie, Universität zu Köln

Gleueler Straße 24

50931 Köln

Phone: 0221/4785674

Fax: 0221/4785022

Email: jan.matthes@uni-koeln.de

      >